LINE in the 13F filings
Lineage Cell Theraputics In · CUSIP 53566V106
New listing in Q3 2024· first held by a tracked manager this quarter, so its new positions are allocations rather than a turn towards it
- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 14 Nov 2024
- latest of these filings; the earliest 5 Nov 2024
- Managers listing it
- 16
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 0 listed it in both
- Shares listed
- 19,429,083
- combined, among listed positions
- Reported value
- $1.5bn
- combined, at the quarter end
Among the 94 comparable managers: 16 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +19,429,083.
Managers listing LINE in Q3 2024
16 of 16 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incnew position · 4,699,854 shares now+4,699,854
- Wellington Management Group LLPnew position · 3,392,389 shares now+3,392,389
- Capital World Investorsnew position · 2,501,764 shares now+2,501,764
- Baillie Gifford & Conew position · 1,714,099 shares now+1,714,099
- Janus Henderson Group Ltdnew position · 1,682,741 shares now+1,682,741
Reductions
No reduction among listed positions.
New positions and exits
New (16)
- T. Rowe Price Associates Inc$368m
- Wellington Management Group LLP$266m
- Capital World Investors$196m
- Baillie Gifford & Co$134m
- Janus Henderson Group Ltd$132m
- D1 Capital Partners LP$82m
- Balyasny Asset Management LLC$81m
- Capital Research Global Investors$78m
- Hudson Bay Capital Management LP$35m
- Altimeter Capital Management LP$31m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 16 | $1.5bn | 16 | 0 |
| Q4 2024 | 12 | $1.1bn | 9 | 7 |
| Q1 2025 | 9 | $1.3bn | 6 | 3 |
| Q2 2025 | 11 | $1.0bn | 8 | 3 |
| Q3 2025 | 7 | $646m | 4 | 4 |
| Q4 2025 | 6 | $481m | 13 | 12 |
| Q1 2026 | 4 | $341m | 13 | 12 |
| Q2 2026 | 4 | $513m | 9 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LINE and WELL →LINE and EQIX →LINE and PLD →Choose a stock to compare with LINE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LINE, latest filings →Back to the 13F Explorer →